European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Educational Webinar with Dr. Mark Zaydman from Washington University School of Medicine in St. Louis, MO
The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity